Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Sal-like protein 4 (SALL4) messenger RNA 3'-untranslated region (3'-UTR) is a critical regulatory segment of the SALL4 transcript, which encodes a zinc-finger transcription factor essential for embryonic development and the maintenance of stem cell pluripotency (Zhang et al., 2015). While SALL4 is typically silenced in most adult tissues, it is frequently reactivated in various malignancies, including hepatocellular carcinoma (HCC) and acute myeloid leukemia (AML), where it acts as a potent oncofetal protein driving tumor growth and self-renewal (Yong et al., 2013). The 3'-UTR contains multiple binding sites for microRNAs (miRNAs) and RNA-binding proteins that post-transcriptionally control the stability and translation efficiency of the SALL4 message (Cheng et al., 2015). Therapeutic strategies targeting this region, such as antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), or miRNA mimics, aim to downregulate SALL4 expression to inhibit oncogenic signaling pathways. Because SALL4 is a key driver of cancer stemness, the 3'-UTR represents a high-value target for precision oncology, although challenges include ensuring delivery to target tissues and avoiding developmental toxicity, as SALL4 is a known neo-substrate for teratogenic drugs like thalidomide (Matyskiela et al., 2018).
Binding to the 3'-untranslated region to induce mRNA degradation or inhibit translation, thereby reducing the expression of the SALL4 oncofetal protein.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sal-like protein 4 messenger RNA 3' untranslated region (SALL4 mRNA 3'-UTR) (SALL4 mRNA 3'-UTR).